Profit and loss information (Tables)

6 Months Ended

Jun. 30, 2026

Receivables from contracts with customers [abstract]

Schedule of Revenue from Sale and Transfer of Goods and Services

The Group derives revenue from the sale and transfer of goods and services over time and at a point in time under the

following major business activities:


			June 30 2026		June 30 2025
	Recognition	Operating segment	US$'000		US$'000
Sale of goods	At a point in time	Precision Medicine	388,210		305,765
Sale of goods	At a point in time	Manufacturing Solutions	83,606		76,807
Royalty income	At a point in time	Precision Medicine	423		55
Provision of services	At a point in time	Manufacturing Solutions	-		15
Provision of services	Over time	Manufacturing Solutions	5,111		3,708
Research and development services	Over time	Precision Medicine	-		15
Research and development services	Over time	Therapeutics	-		3,994
Total revenue from continuing operations			477,350		390,359

Schedule of Employment Costs


	June 30 2026		June 30 2025
	US$'000		US$'000
Salaries and wages	117,683		94,813
Sales commissions	4,914		3,235
Share-based payment charge	12,129		11,585
Non-Executive Directors’ fees	416		386
	135,142		110,019

Schedule of Depreciation and Amortization


	June 30 2026		June 30 2025
	US$'000		US$'000
Amortization of intangible assets	4,204		4,620
Depreciation	6,951		4,965
	11,155		9,585

Schedule of Other Income


	June 30 2026		June 30 2025
	US$'000		US$'000
Other income from collaboration agreements	(40,000)		-
	(40,000)		-

Schedule of Finance Costs


	June 30 2026		June 30 2025
	US$'000		US$'000
Unwind of discount	14,533		12,410
Interest expense on lease liabilities	1,783		1,054
Convertible bond interest expense	5,334		4,911
(Gain) on repurchase of convertible bond	(2,935)		-
Interest expense	303		231
Bank fees	370		236
Finance costs	19,388		18,842